Biocon launches Yesafili biosimilar eye drug in US market

Business Updates View source PDF Explain this filing

BIOCON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.2%Reaction day

₹426.00

prior close

₹429.00

announcement price

After-mkt

timing

Nifty Midcap 150market+1.2%-1.0% vs market

Pharmaceuticals peers, median of 163sector+1.0%-0.7% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Midcap 150 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-1.0

15m

-0.8

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.2+1.2-1.0+1.0-0.7

Next day

-0.2+0.9-1.1+0.8-1.0

-0.2+1.1-1.3+0.3-0.5

+2.5+0.7+1.7+0.7+1.8

+0.1+1.0-0.8+1.5-1.3

+0.0+1.4-1.4+1.3-1.3

+0.3+1.7-1.3+1.6-1.3

15d

-4.0+1.2-5.2+0.9-4.9

-5.6+0.4-6.0+1.7-7.3

-13.2-6.0-7.2+1.9-15.0

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biocon has commercially launched Yesafili (aflibercept-jbvf), a US FDA-approved interchangeable biosimilar of Regeneron's Eylea 2 mg, in the United States as of August 3, 2026. The drug treats eye conditions like wet AMD, macular edema, and diabetic retinopathy. US aflibercept sales were around 5.89 billion dollars in 2023, with about 19.8 million Americans affected by AMD.

Likely market impact

Opens access to a multi-billion dollar US eye-drug market, supporting future revenue growth and biosimilars portfolio expansion.